LATIN AMERICAN COOPERATIVE ONCOLOGY GROUP

Brazil faces significant cancer challenges, including disparities in care and limited access to advanced treatments. BeiGene established a local clinical operations team in 2022, launching over 10 clinical studies and enrolling over 200 patients. Brazil's position as a critical hub for oncology research in Latin America is solidified through collaboration with investigators, clinical sites, and regulators, leveraging a CRO-free operational model to drive cost efficiency and accelerate trial timelines.

Platinum-resistant ovarian cancer's treatment challenge is addressed by the development of the oral, selective GR modulator relacorilant, which aims to block cortisol's antiapoptotic effects in GR-overexpressing solid tumors. The phase 3 ROSELLA study is underway to confirm relacorilant's efficacy with nab-paclitaxel in platinum-resistant ovarian cancer, based on promising phase 2 data showing improved progression-free survival and duration of response.